MODULE-1	ADMINISTRATIVE INFORMATION & PRODUCT INFORMATION
BRAND NAME:	NAVIDOXINE
GENERIC NAME:	Meclizine Hydrochloride & Pyridoxine Hydrochloride Tablets

PRODUCT INFORMATION

Summary of Product Characteristics (SmPC)

1. NAME OF THE MEDICINAL PRODUCT

Name of the Medicinal Product

NAVIDOXINE

(Meclizine Hydrochloride & Pyridoxine Hydrochloride Tablets**)**

Strength

25 mg + 50 mg/ Tablet

1.3 Pharmaceutical Form

Uncoated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each Uncoated tablet contains;

Meclizine Hydrochloride USP..... 25 mg

Pyridoxine Hydrochloride BP..... 50 mg

Excipients. ..... q.s.

3. PHARMACEUTICAL FORM

Uncoated tablets

4. Clinical particulars

Therapeutic indications

Meclizine Hydrochloride & Pyridoxine Hydrochloride Tablet is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:

- Nausea, vomiting and dizziness caused by motion sickness
- Inadequate dietary intake
- Drug-induced deficiency

Posology and method of administration

Vertigo

For the control of vertigo associated with diseases affecting the vestibular system, the recommended dose is 25 to 100 mg daily, in divided dosage, depending upon clinical response.

Motion Sickness

The initial dose of 25 to 50 mg of NAVIDOXINE should be taken one hour prior to embarkation for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.

Contraindications

Meclizine HCl & Pyridoxine is contraindicated in individuals who have shown a previous hypersensitivity to it.

Special warnings and precautions for use Meclizine Hydrochloride

Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.

Patients should avoid alcoholic beverages while taking the drug. Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.

Usage in Children

Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended in children under 12 years of age.

Usage in Pregnancy

Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25 to 50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that meclizine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary.

The Meclizine Hydrochloride Tablets, 25mg contain FD&C Yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&C Yellow #5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when meclizine is administered to a nursing woman.

Hepatic Impairment

The effect of hepatic impairment on the pharmacokinetic of meclizine has not been evaluated. As meclizine undergoes metabolism, hepatic impairment may result in increased systemic exposure of the drug. Treatment with meclizine should be administered with caution in patients with hepatic impairment.

Renal Impairment

The effect of renal impairment on the pharmacokinetics of meclizine has not been evaluated. Due to a potential for drug/metabolite accumulation, meclizine should be administered with caution in patients with renal impairment and in the elderly as renal function generally declines with age.

Drug Interactions

There may be increased CNS depression when meclizine is administered concurrently with other CNS depressants, including alcohol, tranquilizers, and sedatives. (see WARNINGS).

Based on in-vitro evaluation, meclizine is metabolized by CYP2D6. Therefore there is a possibility for a drug interaction between meclizine and CYP2D6 inhibitors.

Pyridoxine Hydrochloride

If symptoms persist or worsen, seek medical advice. Do not exceed the stated dose.

Interaction with other medicinal products and other forms of interaction

Many drugs may alter the metabolism or bioavailability of pyridoxine, including isoniazid, penicillamine and oral contraceptives, which may increase the requirements for pyridoxine.

Pyridoxine hydrochloride may reduce the effect of levodopa, a drug used in the treatment of Parkinsons Disease unless a dopa decarboxylase inhibitor is also given.

Fertility, pregnancy and lactation

Data on exposed pregnancies indicate no adverse effects of pyridoxine in therapeutic doses on pregnancy or the health of the foetus or newborn child, or during lactation.

Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal development, parturition or postnatal development.

Caution should be exercised when prescribing to pregnant women.

Effects on ability to drive and use machines

None known.

Undesirable effects

Long term administration of large doses of pyridoxine is associated with the development of severe peripheral neuritis.

Overdose

a) Symptoms – None reported

b) Treatment – no treatment necessary.

5. Pharmacological properties

Pharmacodynamic properties Meclizine Hydrochloride:

Meclizine Hydrochloride is an antihistamine that shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.

Pyridoxine Hydrochloride:

Pyridoxine hydrochloride is Vitamin B_6. It is converted to pyridoxal phosphate which is the co-enzyme for a variety of metabolic transformations. It is essential for human nutrition.

Pharmacokinetic properties Meclizine Hydrochloride:

Absorption Meclizine is absorbed after oral administration with maximum plasma concentrations reaching at a median Tmax value of 3 hours post-dose (range: 1.5 to 6 hours) for the tablet dosage form. Distribution Drug distribution characteristics for meclizine in humans are unknown. Metabolism The metabolic fate of meclizine in humans is unknown. In an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme, CYP2D6 was found to be the dominant enzyme for metabolism of meclizine. The genetic polymorphism of CYP2D6 that results in extensive-, poor-, intermediate- and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure. Elimination Meclizine has a plasma elimination half-life of about 5-6 hours in humans.

Pyridoxine Hydrochloride:

Pyridoxine hydrochloride is absorbed from the gastrointestinal tract and is converted to the active forms pyridoxal phosphate and pyridoxamine phosphate. It crosses the placental barrier and appears in breast milk. It is excreted in the urine as 4-pyridoxic acid.

Preclinical safety data

Not Applicable

6. Pharmaceutical particulars

List of excipients

Sr. No.	Material name	Specification	Remarks
1.	Microcrystalline cellulose	BP	Diluents
2.	Lactose	BP	Diluents
3.	Starch	BP	Diluents/Binder
4.	Iso propyl alcohol	BP	Solvent
5.	P.V.P.K. 30	BP	Binder
6.	Talcum Powder	BP	Glidant
7.	Magnesium Stearate	BP	Lubricant
8.	Sodium Starch Glycollate	BP	Disintegrant
9.	Colloidal Silicon Dioxide	BP	Glidant

Incompatibilities

Not applicable

Shelf life

36 months

Special precautions for storage

Do not store above 30°C. Store in the original package. Keep container in the outer carton.

Nature and contents of container

Aluminium-PVC Blister
10 X 10 Tablets, 1 x 100 Tablets
10 Blister are packed in carton with pack insert

6.6 Special precautions for disposal and other handling

Not applicable

7. Marketing Authorization Holder

SANGHARSH LIFECARE PVT LTD
A-503, Solitaire Corporate Park, Nr.Divya Bhaskar, S.G.Highway, Makarba, Ahmedabad-380015

8. Marketing Authorization Number

Not Applicable.

9. Date of First Authorization /Renewal of the Authorization

Not Applicable.

10. Date of Revision of the Text

Not Applicable.